11 kinds of traditional Chinese patent medicines and simple preparations included in the new version of the drug catalog are respectively Sunflower Pharmaceutical's 1.1 new drug Ercha Shangqing Pill, Yabao Pharmaceutical's 1.1 new drug Jiuwei Cough relieving Oral Liquid, Chengdu Yongkang Pharmaceutical's 1.1 new drug Qinwei Granules, Kangyuan Pharmaceutical's 3.1 new drug Jichuanjian Granules, Huarun Sanjiu's 3.1 new drug Wenjingtang Granules, Shenwei Pharmaceutical's 3.1 new drug Tongluomingmu Capsules, Yiling Pharmaceutical's 1.1 new drug Tongluo Mingmu Capsules, Jichuan Pharmaceutical's 2.2 new drug Xiaoer Feiqiao Qingre Syrup, Jianmin Group's 1.1 new drug Xiaoer Zibei Xuan Lung Syrup, Yangzijiang Pharmaceutical's 1.1 new drug Yiqi Tongqiao Pill, and Qingfeng Pharmaceutical's 1.2 new drug Zhishi Total Flavone Tablets.

 

 

 

Many traditional Chinese patent medicines and simple preparations have bright spots. Among them, Shenwei Pharmaceutical's Class 3.1 new drug, also known as the innovative classic Chinese medicine formula - Yiguan Jian Granules, was successfully negotiated and included in the 2024 National Medical Insurance Drug Catalog. According to the data, Yiguan decoction granules are mainly used for treating liver yin deficiency, blood dryness and qi stagnation syndrome. Symptoms: Pain in the chest, epigastric region, swallowing acid and vomiting bitterness, dry throat and mouth, red tongue with little saliva, fine and stringy pulse. It also treats hernia accumulation. This drug has been included in multiple guidelines and consensus. Modern pharmacological research has shown that Yiguan decoction granules have the effects of protecting the liver, tumors, stomach, and nourishing yin and soothing the liver. They are widely used in clinical practice, filling the clinical medication gap of liver yin deficiency and blood dryness and qi stagnation in diseases such as chronic gastritis, chronic hepatitis B, liver fibrosis, cirrhosis, primary liver cancer, Sjogren's syndrome, and menopausal syndrome. They are the preferred formula for nourishing yin and soothing the liver in clinical practice.

 

 

 

Yiling Pharmaceutical's 1.1 class innovative traditional Chinese medicine Tongluo Mingmu capsule for the treatment of diabetes retinopathy is the first class B medicine included in the medical insurance catalog. This product is an innovative traditional Chinese medicine developed under the guidance of the theory of collateral disease in traditional Chinese medicine. It is composed of 12 traditional Chinese medicines, including red peony, astragalus, pink kudzu, privet fruit, and Eclipta. It has the function of removing blood stasis, clearing collaterals, supplementing qi, nourishing yin, and stopping bleeding and improving eyesight. Studies have confirmed that it is generally effective in the treatment of diabetes retinopathy, can correct the disorder of glucose metabolism, protect retinal microvessels, protect optic nerve cells, improve the function of qi and collateral, and has good safety, which will fill the blank of "deficiency of both qi and yin, blood stasis and collateral obstruction" syndrome of diabetes retinopathy.

 

 

 

The Wenjing Decoction Granules of China Resources Sanjiu was included in the national drug catalog for the first time through negotiation. The prescription of this traditional Chinese patent medicines and simple preparations was derived from the Complete Prescription of Women by Song Chen Ziming, and has been included in the Catalog of Ancient Classic Famous Prescriptions (the first batch): "If the channel is not clear, it will be cold around the umbilical cord, and its pulse will be deep and tight. This is because the cold air is in the blood chamber, and the blood will not coagulate, and the accumulated blood will be rushed by the qi. The new blood will fight with the old blood, so it will be painful. It is better to warm the meridian decoction."

 

 

 

In addition, Longmu Pediatric Series products under Jianmin Group - Pediatric Purple Beixuan Lung Syrup - have also been officially included in the 2024 National Medical Insurance Catalogue. It is reported that this drug is the first Class 1.1 innovative drug specifically designed to treat children with acute bronchitis and wind heat invading the lungs, bringing new treatment options to patients.

 

 

 

Industry insiders point out that the sales scale of related products of various companies is relatively small, and inclusion in the medical insurance catalog will help promote the market and increase sales scale.